Zobrazeno 1 - 6
of 6
pro vyhledávání: '"James G. Kublin"'
Autor:
Kathryn Therese. Mngadi, Vijay L. Mehra, Kristen W. Cohen, Glenda Gray, Shannon Grant, Zoe Moodie, Brodie Daniels, Marguerite Koutsoukos, Sanjay Phogat, Peter B. Gilbert, M. Juliana McElrath, Nonhlanhla N. Mkhize, Chenchen Yu, Georgia D. Tomaras, Olivier Van Der Meeren, Linda-Gail Bekker, James G. Kublin, Nicole Frahm, Carlos A. DiazGranados, Mary Allen, Lawrence Corey, Fatima Laher, Carter Bentley, Mookho Malahleha, Michael Pensiero, Lynn Morris, Kevin O. Saunders, Nicole L. Yates, Nicole Grunenberg, David C. Montefiori, Craig Innes
Publikováno v:
PLoS Medicine
PLoS Medicine, Vol 17, Iss 2, p e1003038 (2020)
PLoS Medicine, Vol 17, Iss 2, p e1003038 (2020)
Background HVTN 100 evaluated the safety and immunogenicity of an HIV subtype C pox-protein vaccine regimen, investigating a 12-month booster to extend vaccine-induced immune responses. Methods and findings A phase 1–2 randomized double-blind place
Autor:
Allan C. deCamp, Mary Allen, James G. Kublin, M. Juliana McElrath, Mina C. Hosseinipour, Craig Innes, Zoe Moodie, Giuseppe Pantaleo, Jack Heptinstall, Chenchen Yu, Nonhlanhla N. Mkhize, Nicole Frahm, Peter B. Gilbert, Erica Andersen-Nissen, Maurine D. Miner, Linda-Gail Bekker, Fatima Laher, Sarita Naidoo, Glenda Gray, Kristen W. Cohen, Julia Hutter, Hvtn trial teams, Philipp Mann, Lucas Maganga, David C. Montefiori, Lynn Morris, Ralf Wagner, One Dintwe, Georgia D. Tomaras, Nicole L. Yates, Nicole Grunenberg, Stephen R. Walsh, Michael E Herce
Publikováno v:
PLoS Medicine
PLoS Medicine, Vol 17, Iss 5, p e1003117 (2020)
PLoS Medicine, Vol 17, Iss 5, p e1003117 (2020)
Background DNA plasmids promise a pragmatic alternative to viral vectors for prime-boost HIV-1 vaccines. We evaluated DNA plasmid versus canarypox virus (ALVAC) primes in 2 randomized, double-blind, placebo-controlled trials in southern Africa with h
Autor:
Zoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg, One B Dintwe, Faatima Laher Omar, Jia J Kee, Linda-Gail Bekker, Fatima Laher, Nivashnee Naicker, Ilesh Jani, Nyaradzo M Mgodi, Portia Hunidzarira, Modulakgota Sebe, Maurine D Miner, Laura Polakowski, Shelly Ramirez, Michelle Nebergall, Simbarashe Takuva, Lerato Sikhosana, Jack Heptinstall, Kelly E Seaton, Stephen De Rosa, Carlos A Diazgranados, Marguerite Koutsoukos, Olivier Van Der Meeren, Susan W Barnett, Niranjan Kanesa-Thasan, James G Kublin, Georgia D Tomaras, M Juliana McElrath, Lawrence Corey, Kathryn Mngadi, Paul Goepfert, HVTN 107 Protocol Team
Publikováno v:
PLoS Medicine, Vol 21, Iss 3, p e1004360 (2024)
BackgroundAdjuvants are widely used to enhance and/or direct vaccine-induced immune responses yet rarely evaluated head-to-head. Our trial directly compared immune responses elicited by MF59 versus alum adjuvants in the RV144-like HIV vaccine regimen
Externí odkaz:
https://doaj.org/article/909a7c021d8247d2955cca75b0f8a084
Autor:
Shelly Karuna, Shuying Sue Li, Shannon Grant, Stephen R Walsh, Ian Frank, Martin Casapia, Meg Trahey, Ollivier Hyrien, Leigh Fisher, Maurine D Miner, April K Randhawa, Laura Polakowski, James G Kublin, Lawrence Corey, David Montefiori, HVTN 405/HPTN 1901 Study Team
Publikováno v:
PLoS Medicine, Vol 18, Iss 12, p e1003868 (2021)
BackgroundPeople infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) experience a wide range of clinical manifestations, from asymptomatic and mild illness to severe illness and death, influenced by age and a variety of comorbi
Externí odkaz:
https://doaj.org/article/264da4fa22534ccfbdbd68057f09e889
Autor:
Zoe Moodie, Stephen R Walsh, Fatima Laher, Lucas Maganga, Michael E Herce, Sarita Naidoo, Mina C Hosseinipour, Craig Innes, Linda-Gail Bekker, Nicole Grunenberg, Philipp Mann, Chenchen Yu, Allan C deCamp, Maurine D Miner, Nicole L Yates, Jack Heptinstall, Nonhlanhla N Mkhize, One Dintwe, Nicole Frahm, Kristen W Cohen, Mary Allen, Julia Hutter, Ralf Wagner, Giuseppe Pantaleo, M Juliana McElrath, Georgia D Tomaras, Lynn Morris, David C Montefiori, Erica Andersen-Nissen, Glenda E Gray, Peter B Gilbert, James G Kublin, NIAID HVTN 100 and HVTN 111 trial teams
Publikováno v:
PLoS Medicine, Vol 17, Iss 5, p e1003117 (2020)
BackgroundDNA plasmids promise a pragmatic alternative to viral vectors for prime-boost HIV-1 vaccines. We evaluated DNA plasmid versus canarypox virus (ALVAC) primes in 2 randomized, double-blind, placebo-controlled trials in southern Africa with ha
Externí odkaz:
https://doaj.org/article/7c285a3459774f30806f3e5507798d93
Autor:
Fatima Laher, Zoe Moodie, Kristen W Cohen, Nicole Grunenberg, Linda-Gail Bekker, Mary Allen, Nicole Frahm, Nicole L Yates, Lynn Morris, Mookho Malahleha, Kathryn Mngadi, Brodie Daniels, Craig Innes, Kevin Saunders, Shannon Grant, Chenchen Yu, Peter B Gilbert, Sanjay Phogat, Carlos A DiazGranados, Marguerite Koutsoukos, Olivier Van Der Meeren, Carter Bentley, Nonhlanhla N Mkhize, Michael N Pensiero, Vijay L Mehra, James G Kublin, Lawrence Corey, David C Montefiori, Glenda E Gray, M Juliana McElrath, Georgia D Tomaras
Publikováno v:
PLoS Medicine, Vol 17, Iss 2, p e1003038 (2020)
BackgroundHVTN 100 evaluated the safety and immunogenicity of an HIV subtype C pox-protein vaccine regimen, investigating a 12-month booster to extend vaccine-induced immune responses.Methods and findingsA phase 1-2 randomized double-blind placebo-co
Externí odkaz:
https://doaj.org/article/a8f5e1efa20e4dca897e71b9fcfdaef2